tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Sana Biotechnology Reports Non-Cash Impairment Losses

Story Highlights
  • Sana Biotechnology reported $90.1 million in cash and expects $40-45 million in impairment losses.
  • The UP421 trial showed successful pancreatic beta cell transplantation without immunosuppression.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Sana Biotechnology Reports Non-Cash Impairment Losses

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Sana Biotechnology ( (SANA) ) has issued an update.

In a recent update, Sana Biotechnology reported preliminary financial information indicating approximately $90.1 million in cash, cash equivalents, and marketable securities as of July 31, 2025. The company also announced non-cash impairment losses estimated between $40.0 million and $45.0 million related to its Bothell and Seattle facilities, following changes in its business plans and manufacturing strategies. Additionally, Sana Biotechnology shared positive clinical results from the UP421 trial in June 2025, demonstrating successful transplantation of pancreatic beta cells without immunosuppression, with all primary and secondary endpoints met. The company continues to advance its pre-clinical development of SC451 and is optimistic about its future manufacturing and testing plans.

The most recent analyst rating on (SANA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Sana Biotechnology stock, see the SANA Stock Forecast page.

Spark’s Take on SANA Stock

According to Spark, TipRanks’ AI Analyst, SANA is a Underperform.

Sana Biotechnology’s overall stock score is primarily impacted by significant financial challenges, including consistent losses and a lack of revenue. Despite some improvements in balance sheet stability and operating cash flow, the bearish technical indicators and negative valuation metrics underscore the need for strategic changes to achieve growth and profitability.

To see Spark’s full report on SANA stock, click here.

More about Sana Biotechnology

Sana Biotechnology operates in the biotechnology industry, focusing on the development of cell and gene therapy products. The company is engaged in advancing therapeutic solutions through its hypoimmune platform technology, which aims to enable the survival of transplanted cells without immunosuppression.

Average Trading Volume: 4,953,492

Technical Sentiment Signal: Hold

Current Market Cap: $960.9M

For detailed information about SANA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1